NeOnc Technologies (NTHI) said Monday it expects full enrollment in a phase 2a trial for its therapeutic candidate NEO100-01 by September, with just six patients remaining to reach the 25-patient target.
The trial is evaluating NEO100, which is intended for the treatment of malignant gliomas, particularly IDH1 mutant Grade III and IV astrocytomas. The read-out for the trial's data is expected early next year, the company said.
The drug candidate has been granted orphan drug and fast-track status by the US Food and Drug Administration, according to the company.
Price: 8.64, Change: -0.27, Percent Change: -3.03
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。